Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on September 23, 2008
JNCI Journal of the National Cancer Institute 2008 100(19):1350-1351; doi:10.1093/jnci/djn356
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/19/1350    most recent
djn356v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Brower, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brower, V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2008.

NEWS

Cancer-killing Viruses Assist Gene Therapies

Vicki Brower, This is the second in a two-part series on gene therapy.

The first 10% of the full text of this article appears below.

In the beginning of the last century, scientists were surprised to discover that cancer patients infected with a viral illness sometimes experienced tumor regressions, as did patients given attenuated viral vaccines. By the end of the century, researchers performing early gene therapy experiments were using viruses as delivery vehicles, or vectors, to insert genes into cells, taking advantage of the viruses’ innate ability to infect cells, replicate, cause cell death, release viral particles, and spread.

"In the first human gene therapy trials in the 1990s, only nonreplicating viruses were used as vectors because of safety concerns," said Evanthia Galanis, M.D., professor of oncology at the Mayo Clinic in Rochester, Minn. "This taught us an important lesson: Using nonreplicating viruses resulted in infection or therapeutic gene expression in only a small percentage of tumor cells.


Figure Removed (Available Only in the Full Text)
View larger version (128K):



  		Evanthia Galanis, M.D.

 
. . . [Full Text of this Article]

Early Steps

Clinical Trials Moving Forward


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
L. Menotti, G. Nicoletti, V. Gatta, S. Croci, L. Landuzzi, C. De Giovanni, P. Nanni, P.-L. Lollini, and G. Campadelli-Fiume
Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells
PNAS, June 2, 2009; 106(22): 9039 - 9044.
[Abstract] [Full Text] [PDF]